WebIn Drug Rediscovery Protocol (DRUP), patients with treatment-refractory solid malignancies receive offlabel drugs based on tumor molecular profiles while whole-genome sequencing (WGS) is performed on baseline tumor biopsies. The primary endpoint was clinical benefit (CB; defined as objective response or stable disease ≥ 16 weeks … WebAll patients who receive treatment with a drug available in the protocol will be followed for standard efficacy outcomes including tumor response, progressionfree - and …
Efficacy and toxicity of vemurafenib and cobimetinib in relation to ...
WebOct 1, 2024 · The potential of the Drug Rediscovery protocol is illustrated by the identification of a successful cohort of patients with microsatellite instable tumours who received nivolumab (clinical benefit ... WebFeature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications. clelia\\u0027s room napoli
The Drug Rediscovery Protocol (DRUP Trial) (DRUP)
Web7182 - Drug Rediscovery Protocol: Expanded use of existing anticancer drugs Background. Large-scale genetic tumor profiling can identify increasing numbers of … WebOct 1, 2024 · Thus, to choose an alternative drug, a doctor working under the Drug Rediscovery protocol would look up a drug that has been approved for treating a similar type of mutation. WebUnique Protocol ID: M15DRU : Brief Title: The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Official Title: A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile tapu randevu sorgulama